Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study 50 patients with multiple Basal Cell Carcinoma (BCC)
who will be receiving Photodynamic Therapy (PDT) as treatment for their tumors. This study
wants to establish the optimal conditions for treating BCC tumors with PDT. Previous research
suggests that taking Vitamin D prior to the start of PDT could help improve the effectiveness
of the treatment in eliminating the BCC. Overall, this study will help establish oral Vitamin
D3/PDT as a new combination therapy for skin cancer (BCC).
Photodynamic Therapy (PDT) is an investigational (experimental) technique that works by
combining a photosensitizing topical agent and an intense light source to kill tumor cells.
PDT is currently approved for the treatment of BCC in Europe, Canada, and Australia. However,
it is experimental in the United States because it is not approved by the Food and Drug
Administration (FDA).
Phase:
Phase 1
Details
Lead Sponsor:
Case Comprehensive Cancer Center The Cleveland Clinic
Collaborators:
Harvard Medical School University of Arizona
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins